Keyphrases
Advanced Cancer
100%
Phase I Trial
100%
Mistletoe
100%
Mistletoe Extract
100%
Quality of Life
75%
Stable Disease
75%
Helixor
75%
Nausea
50%
Solid Tumors
50%
In(III)
50%
Quality of Life Improvement
50%
Disease Control
50%
Relapsed or Refractory
25%
High Dose
25%
Rate of Increase
25%
Chemotherapy
25%
Patients with Cancer
25%
Supportive Therapy
25%
Partial Response
25%
Phase II Trial
25%
Dose Level
25%
Carcinoembryonic Antigen
25%
Treatment-related Adverse Events
25%
Metastatic Tumor
25%
Functional Assessment of Cancer Therapy
25%
Objective Response
25%
Heavily Pretreated
25%
Follow-up Interval
25%
Carbohydrate Antigen 125 (CA125)
25%
Disease Control Rate
25%
Tumor Marker
25%
Treatment-related
25%
Intravenous Administration
25%
Lack of Data
25%
Escalating Dose
25%
Effects on Survival
25%
Target Lesion
25%
ME Effect
25%
Chemotherapy Tolerability
25%
Medicine and Dentistry
Advanced Cancer
100%
Phase I Trials
100%
Diseases
100%
Quality of Life
83%
Solid Malignant Neoplasm
50%
Viscum Album Extract
50%
Nausea
33%
Chill
33%
Cancer Therapy
16%
Adverse Event
16%
Cancer
16%
Drug Megadose
16%
Carcinoembryonic Antigen
16%
Functional Assessment
16%
Phase II Trials
16%
Tumor Antigen
16%
Tumor Marker
16%
Target Lesion
16%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
100%
Phase I Trials
100%
Mistletoe
100%
Diseases
85%
Solid Malignant Neoplasm
42%
Viscum Album Extract
42%
Malignant Neoplasm
28%
Nausea
28%
Chemotherapy
28%
Chill
28%
Adverse Event
14%
Phase II Trials
14%
Tolerability
14%
Tumor Marker
14%
Tumor Antigen
14%
Carcinoembryonic Antigen
14%